Voxilaprevir

Voxilaprevir is a pan-genotypic hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease inhibitor. It inhibits replication of wild-type HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (EC50s = 1.9-6.6 nM in replicon assays). Voxilaprevir also inhibits replication of mutant HCV genotypes containing NS3 resistance-associated substitutions (EC50s = 3.1, 2.7, and 4 nM for HCV genotypes 1a Q80K, 1a R155K, and 1b D168E, respectively). Formulations containing voxilaprevir have been used in the treatment of chronic HCV infection.Formal Name: N-[[[(1R,2R)-2-[5,5-difluoro-5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(3S,4R)-3-ethyl-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]-cyclopropanecarboxamide, cyclic (1R->2R)-ether. CAS Number: 1535212-07-7. Synonyms: GS-9857. Molecular Formula: C40H52F4N6O9S. Formula Weight: 868.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 1 mg/ml. lambdamax: 217 nm. SMILES: O=C([C@H]([C@H](CC)[C@]([H])(C1)OC2=NC3=CC(OC)=CC=C3N=C2C(F)(CCCC[C@@]4([H])[C@](C4)([H])OC(N[C@H]5C(C)(C)C)=O)F)N1C5=O)N[C@]6([C@@H](C6)C(F)F)C(NS(=O)(C7(CC7)C)=O)=O. InChi Code: InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1. InChi Key: MZBLZLWXUBZHSL-FZNJKFJKSA-N.